Abstract: The present invention relates to the use of posttranslational modification inhibitors, such as isoprenylation inhibitors, to inhibit activation of phagocyte NADPH oxidase and respiratory burst. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.
Abstract: An agent for the prevention and treatment of inflammatory bowel disease (IBD) containing at least one of zinc L-carnosine salts and complexes as an active ingredient. A use of the zinc L-carnosine salts or complexes and a therapeutic method of IBD by using the same are also disclosed.
Abstract: The present invention relates to the regulation of blood sugar levels. Excessively high, excessively low and fluctuations of the blood sugar levels are regulated. The action component is constituted by acetic acid, it being unimportant whether the acetic acid is directly applied or administered, or forms or cleaves in the body.
Abstract: The object of the present invention is the manufacture of a medicine for the use of glycosaminoglycans in the prevention and treatment of some pathologies caused by diabetes, like diabetic nephropathy and diabetic neuropathy.The effectiveness of glycosaminoglycans in the prevention and treatment of said pathologies has been shown by the treatment with some glycosaminoglycans of male albino rats made diabetic by treatment with streptozotocin or alloxan and by the subsequent determination of morphological and clinical parameters like the thickness of the glomerular basal membrane, the number of the glomerular anionic charges and albuminuria in case of diabetic nephropathy, and like the levels of substance P and Met-Enkephalin in some intestinal zones, like duodenum and jejunum, in case of diabetic neuropathy.
Abstract: A topical therapeutic preparation which contains an adrenocortical hormone and hyaluronic acid, the amount of said adrenocortical hormone being lower than the usual clinical dose of it, is used for combatting a skin disease.
Abstract: The present invention relates to an anti-ulcer agent comprising a compound represented by the following general formula I as the effective ingredient, and a novel chalcone derivative included in the compound represented by this general formula I: ##STR1## wherein X and Y independently stand for a hydrogen atom or together form a single bond, R.sub.1 stands for a hydroxyl group, an acetoxy group, a carboxymethoxy group or a methoxycarbonylmethoxy group, R.sub.2 stands for a hydrogen atom, an isoprenyl group, isopentyl group or a propyl group, R.sub.3 stands for a hydroxyl group or a methoxy group, R.sub.4 stands for a hydrogen atom, a hydroxyl group or a methoxy group, R.sub.5 stands for a hydrogen atom, a hydroxyl group, a methoxy group or an isopentyl group, R.sub.6 stands for a hydroxyl group, a methoxy group or a carboxymethoxy group, and R.sub.7 stands for a hydrogen atom or a methoxy group.
Abstract: The present invention is concerned with the use of a compound of formula (I) ##STR1## wherein --W-- is ##STR2## wherein Z is --V(CH.sub.2).sub.b CO.sub.2 H where b is 1 or 2 and V is oxygen when b is 1 or methylene when b is 2;X is hydrogen, cyano, or --C.tbd.CH; andthe dotted line represents an optional double bond;and physiologically functional derivatives thereof,in the treatment of congestive heart failure.
Abstract: A method of accelerating the permeation of drugs in topical and transdermal delivery of a drug in which a drug is applied to the skin in combination with organosilicon compounds which are carboxyalkyl functional polysiloxanes and alkylsulphoxide functional polysiloxanes. The organosilicon compound may be applied to the skin neat or in the form of a solvent solution containing the organosilicon compound.
Type:
Grant
Filed:
June 26, 1992
Date of Patent:
August 3, 1993
Assignee:
Dow Corning France S.A.
Inventors:
Andre L. R. Colas, Jonathan Hadgraft, Vivien L. C. Moffat, Franck A. D. Renauld
Abstract: An embonic acid salt of azelastine is disclosed which does not possess the bitter taste of azelastine, and which therefore is suitable for orally administered formulations.
Type:
Grant
Filed:
October 15, 1990
Date of Patent:
August 3, 1993
Assignee:
Asta Pharma Aktiengesellschaft
Inventors:
Gerhard Scheffler, Dieter Sauerbier, Jurgen Engel
Abstract: Noninfectious inflammatory and hyperpigmentation skin diseases, thermal injuries and premalignant skin tumors induced by radiation or virus, in both humans and animals, are treated with topical formulations of an ester or amide of a monocarboxylic acid, the acid moiety of which is 9 to 18 carbon atoms.
Abstract: This invention relates to the novel use of N-acetyl glucosamine for the treatment of gastrointestinal tract disorders by restoring and maintaining the integrity and normal function of the gastrointestinal tract. A method of treating gastrointestinal mucous membrane disorder in a human being comprising feeding the human being a therapeutic amount of N-acetyl glucosamine on a periodic basis.
Abstract: This invention relates to the use of butylurea as a contraceptive agent. Butylurea may be used either alone or with a pharmaceutically acceptable carrier, and may be used in conjunction with conventional contraceptive means to abrogate sperm motility.
Type:
Grant
Filed:
March 6, 1992
Date of Patent:
July 20, 1993
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Type:
Grant
Filed:
February 19, 1992
Date of Patent:
July 6, 1993
Assignee:
Glaxo Group Ltd.
Inventors:
Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
Abstract: The invention relates to a method of preventing or treating gastrointestinal ulcer disease and microvascular injury in a mammal comprising administering to said mammal a pyrazole derivative alone or in combination with an ulcerogenic agent. The invention further relates to pharmaceutical compositions comprising a pyrazole derivative in combination with an ulcerogenic therapeutic agent to inhibit or prevent the ulcerogenic effect of that agent.
Abstract: The present invention provides a method of treatment and/or prophylaxis of the human or animal body to combat Molluscum Contagiosum, said treatment comprising topically administering a therapeutically or prophylactically effective amount of a physiologically acceptable lithium compound to affected areas on said body.It also extends to pharmaceutical compositions comprising a physiologically acceptable lithium compound together with at least one keratolytic and/or skin penetration assisting agent and at least one pharmaceutically acceptable carrier or excipient.
Abstract: An antipruritic composition for an oral medicine, injection, and external medicine, comprising an effective amount of a chelated zinc (e.g., zinc picolinate) as an antipruritic agent.
Abstract: A gel formulation for topical administration with enhanced skin penetration properties comprising a therapeutically effective amount of an imidazole antifungal agent, either by itself or in combination with a steroid anti-inflammatory agent, in a vehicle system that includes lauryl alcohol is disclosed.
Type:
Grant
Filed:
September 25, 1989
Date of Patent:
June 15, 1993
Assignee:
Bristol-Myers Squibb Company
Inventors:
Hemanshu S. Shah, Susan Genier, Cheng D. Yu, Bhiku Patel
Abstract: A method is provided for treating human patients who have Lymes disease by using a psoralen compound, preferably administered in a dosage of 0.3 to 0.7 mg/kg, and activating same either in vitro or in vivo using electromagnetic radiation of a prescribed activating wavelength. The activation of the psoralen compound in the presence of a blood fraction from a patient suffering from Lymes disease produces a composition which will stimulate an effective immune response to the Lymes disease on the part of the patient.
Abstract: This invention pertains to the novel use of N-acetyl glucosamine as a cytoprotective agent for persons afflicted with psoriasis by restoring integrity and normal function of skin. A method of treating psoriasis in a human being comprising feeding the human being a therapeutic amount of N-acetyl glucosamine, or a pharmaceutically acceptable salt thereof, on a periodic basis.